“Recognising gender difference is essential for Parkinson’s research”
Women and Parkinson's
Author: Marina PicilloPublished: 5 December 2019
Prep: Cook: Serves:
In the sixth in our Women and Parkinson’s series, Italian neurologist Marina Picillo shares her findings from studies focussing on gender differences in Parkinson’s, highlights the role cultural bias plays in the results – and reflects on how research into such differences is a relatively “new phenomenon”
I started working in Parkinson’s research when I was in medical school, and developed an interest in gender differences within the condition about six years ago. I began looking into how non-motor symptoms affect men and women differently – with one study revealing that despite women experiencing higher rates of anxiety, depression and panic attacks than men, they remain largely untreated. Men and women experience very different problems. Recognising that is essential for Parkinson’s research purposes – and to ensure better treatment for patients.
The acknowledgment of gender differences in the medical field is quite a new phenomenon – it only started about 30 years ago. It took a while until it filtered down into Parkinson’s research, and I think we are still a little bit behind compared to other research fields. This is probably because two thirds of people with Parkinson’s are men and so the data is dramatically driven by men. But the mentality is changing. The design of studies and the treatment of patients is slowly being given more thought as researchers, the media and the patients themselves call for change.
Diagnostic delays and dyskinesia
Throughout my research I have come across a number of issues that are specific to women. Women are more prone to developing dyskinesia – uncontrollable, involuntary movements that can be a side-effect of levodopa. Some data suggests this is because women have a lower body weight than men, and clinicians prescribe the same dose regardless. Our follow up studies aim to find out more about the metabolism rate of levodopa as we believe that will be different according to gender. If that’s the case, it could seriously impact the way clinicians prescribe the drug in the future.
There’s also the ‘diagnostic delay’ to consider. According to research, on average women are diagnosed a few years later than men. There are a few explanations for this. Parkinson’s is not only less frequent in women, but also appears later in women than men. This is because oestrogen, the primary female sex hormone, is thought to play a ‘protective role’ in the development of Parkinson’s.
Women also generally visit specialists later than men. This may be because they pay less attention to themselves and their health as caregivers. Generally they’re likely to be less involved with their own care – which is an important psychosocial aspect to think about.
I was recently involved in a study which showed that an active sex life improves motor and non-motor symptoms – and quality of life – in people with Parkinson’s, although the results actually only applied to men. This is due to two things. One, women were simply less represented in the study than men. And generally women are less willing to talk about sexual issues than men due to cultural bias.
Women as caregivers
The next topic I’d like to focus my research on is why women are less likely to undergo complex treatments like deep brain stimulation (DBS). It’s a paradox, since women experience worse motor and non-motor fluctuations and more disabling dyskinesia. I think cultural reasons are once more at play here. Generally, worldwide, women have a central role in caring for their families. When a woman is sick, or has to take time off, this impacts on the whole family and causes difficulties. I would like to find out more about why women feel like this, and why there is such a gap in the uptake of these beneficial treatments.
More widely, I would like to see more research into women with young onset Parkinson’s – particularly for those who might still be thinking about having children. There is very little research available on this subject currently.
Though there aren’t symptoms that are unique to women, there are certainly issues that are unique to women with Parkinson’s. There has been progress, and everything is changing – but we still have some way to go.
Need to know: Marina Picillo is a researcher at the Centre for Neurodegenerative Diseases at the University of Salerno, Italy and has authored over 40 research papers. She completed a clinical and research fellowship at the University of Toronto, Canada, where she worked with advanced treatments for Parkinson’s such as DBS.
Parkinson’s and research: the facts
Motor fluctuations, including levodopa-induced dyskinesia, are more common in women with Parkinson’s
Women with Parkinson’s experience a more rapid disease progression than men – and a lower survival rate
Women with Parkinson’s report higher rates of depression and anxiety than men
Women and Parkinson’s: Our campaign
It is estimated that three million women worldwide are living with Parkinson’s – yet their specific needs and experiences are often ignored, leading to disparities in diagnosis, treatment and medication. Each week, we’ll be sharing the little-heard stories of women with the condition to find out how their lives are being affected by a shocking data gap when it comes to women and Parkinson’s. This is just the start.
We want to raise awareness of women’s experience of the condition within the medical profession, so that women’s symptoms are taken seriously.
We think more research is needed into the impact of Parkinson’s on women, so that they can benefit from tailored medication and treatment.
We want to explore ways to offer better support for those women managing the condition alongside caring responsibilities.
Join us – #WomenAndParkinsons.
For more information on women and Parkinson’s please visit the EPDA website.
If you have a story to tell about being a woman with Parkinson’s – or some information about the impact of the condition on women for us to share with the global Parkinson’s community – please get in touch.
Innovative remote management gait guidance system is to launch soon
4 weeks ago
Plant-based compounds could treat chronic pain in Parkinson’s, study finds
A six-year study has found that chronic pain in people with Parkinson’s is linked to a gene involved with how the brain responds to cannabis compounds. The investigation examined why some people with the condition experience persistent pain – and the impact it has on their work, daily life and social relationships. Conducted by researchers at Manchester’s Salford Royal Foundation Trust, UK, and funded by Parkinson’s UK, it is the largest study to investigate chronic pain in people with Parkinson’s. Dr Monty Silverdale, consultant neurologist at Greater Manchester Centre, said: “This study is significant because it shows the important role of genetics in chronic pain in Parkinson’s. “Our findings suggest that cannabis-based compounds may be worth investigating as a treatment for pain in Parkinson’s.”
Could playing table tennis help reduce Parkinson’s symptoms?
Researchers at Fukuoka University, Japan, have found that playing table tennis may help alleviate motor symptoms in Parkinson’s. As part of the study, 12 people with Parkinson’s with an average age of 73 played a five-hour session of table tennis every week for a period of six months. The sessions were developed specifically for people with the condition by experienced table tennis players from the university’s department of sports science. The participants were evaluated after three months and at the end of the study. At both evaluations, participants had reduced symptoms – showing improvement in speech, handwriting, walking and hand tremors. Two participants reported side-effects of backache and falling. Study author Ken-ichi Inoue, MD, of Fukuoka University said: “While this study is small, the results are encouraging because they show ping pong, a relatively inexpensive form of therapy, may improve some symptoms of Parkinson’s disease. A much larger study is…
‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s
Researchers have discovered that a molecule called BT13 could have potential to treat Parkinson’s. The study, conducted by scientists from the University of Helsinki, Finland, found that mice injected with the BT13 molecule had an increase in dopamine levels in the brain. Their findings also suggested that the molecule could lead to a new drug treatment to protect the brain cells that produce dopamine. Dopamine helps coordinate movement, but people with Parkinson’s have normally lost between 70 and 80% of the brain cells that produce the neurotransmitter when they are diagnosed with the condition. Professor David Dexter, Deputy Director of Research at Parkinson’s UK – which co-funded the study – said: “People with Parkinson’s desperately need a new treatment that can stop the condition in its tracks, instead of just masking the symptoms. “More research is needed to turn BT13 into a treatment to be tested in clinical trials, to…